Short answer: In a first-in-human phase 1 and early phase 2 trial, four of 27 people (14.8%) treated at the selected biological doses of invikafusp alfa, or invika, had confirmed tumor shrinkage of more than 30%. Disease had not progressed at the assessment point in 16 of 27 (59.3%). These are preliminary, uncontrolled results in…
Short answer: A study released on October 23, 2026, used a UK school-leaving reform as a natural experiment. People pushed to remain in school until age 16 had an estimated 0.88-percentage-point lower incidence of Alzheimer’s disease and related dementias before age 65. That is evidence about a 1972 compulsory-schooling policy—not proof that any adult can…
Short answer: In a small study of 13 people staying in an epilepsy monitoring unit at the Hospital of the University of Pennsylvania, a seizure-detection model generated about 80% fewer false alarms over the hospital stay after it learned from patients’ feedback. That is a promising result for a supervised inpatient prototype—not proof that a…
Bottom line: No human weight-loss effect was established. A study published in Nature on 14 October 2026, and described by the US National Institutes of Health the same day, connected use of some angiotensin receptor blockers (ARBs) with detectable brown fat in patient records. Researchers then tested losartan in brown-fat cells and mice. They did…
What an NIH-supported sleep-study ECG model predicted, where it added value, and why it does not yet change screening or care.
What WHO’s 2000–2023 estimates say about life expectancy, healthy life expectancy, NCDs, dementia and mental health—and what the figures cannot show.
South Korea’s 2025 KNHANES estimated obesity prevalence at 49.1% among adult men and 59.0% among men in their 30s. Here is what the provisional survey can—and cannot—show.